Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity

Drug Metabolism Reviews

Volumn 47, Issue 1, 2015, Pages 29-44

  Coen, Muireann ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Acetaminophen; Liquid chromatography mass spectrometry; Metabolic phenotyping; Metabolomics metabonomics; NMR spectroscopy

Indexed keywords

ACYLCARNITINE; BIOLOGICAL MARKER; CARBON; GLUTATHIONE; PARACETAMOL; XENOBIOTIC AGENT; ANALGESIC AGENT;

CARBON METABOLISM; DRUG EXCRETION; DRUG INFORMATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SCREENING; ENVIRONMENTAL FACTOR; GLUTATHIONE METABOLISM; HUMAN; IN VIVO STUDY; LIVER TOXICITY; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; REVIEW; XENOBIOTIC METABOLISM; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; LIVER; METABOLISM; PRECLINICAL STUDY; PROCEDURES; TOXIC HEPATITIS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; PHENOTYPE;

EID: 84929455988     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.982865     Document Type: Review

References (87)

1. Bales JR, Bell JD, Nicholson JK, et al. (1988). Metab olic profiling of body fluids by proton NMR: Self-poisoning episodes with paracetamol (acetaminophen). Magn Reson Med 6:300-306.
2. Bales JR, Higham DP, Howe I, et al. (1984a ). Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multicomponent analysis of urine. Clin Chem 30:426-432.
3. Bales JR, Nicholson JK, Sadler PJ. (1985). Two-dimensional proton nuclear magnetic resonance ' 'maps'' of acetaminophen metabolites in human urine. Clin Chem 31:757-762.
4. Bales JR, Sadler PJ, Nicholson JK, Timbrell JA. (1984b ). Urinary excretion of acetaminophen and its metabolites as studied by proton NMR spectroscopy. Clin Chem 30:1631-1636.
5. Beckonert O, Coen M, Keun HC, et al. (2010). High-resolution magicangle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 5:1019-1032.
6. Beckonert O, Keun HC, Ebbels TM, et al. (2007). Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2:2692-2703.
7. Benton HP, Want E, Keun HC, et al. (2012). Intra-and interlaboratory reproducibility of ultra performance liquid chromatography-time-offlight mass spectrometry for urinary metabolic profiling. Anal Chem 84:2424-2432.
8. Bernal W, Auzinger G, Dhawan A, Wendon J. (2010). Acute liver failure. Lancet 376:190-201.
9. Bernal W, Hyyrylainen A, Gera A, et al. (2013). Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 59:74-80.
10. Bhattacharyya S, Pence L, Beger R, et al. (2013). Acylcarnitine profiles in acetaminophen toxicit y in the mouse: Comparison to toxicity, metabolism and hepatocyte regeneration. Metabolites 3:606-622.
11. Bi H, Li F, Krausz KW, et al. (2013). Targeted metabolomics of serum acylcarnitines evaluates hepatopro tective effect of Wuzhi tablet (Schisandra sphenanthera extract) against acute acetaminophen toxicity. Evid Based Complement Alternat Med 2013:985257.
12. Calpena E, Casado M, Martinez-Rubio D, et al. (2013). 5-Oxoprolinuria in heterozygous patients for 5-oxoprolinase (OPLAH) missense changes. JIMD Rep 7:123-128.
13. Chan EC Pasikanti KK Nicholson JK. 2011 Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc 6 1483-1499.
14. Chen C, Krausz KW, Idle JR, Gonzalez FJ. (2008). Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysi s of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem 283:4543-4559.
15. Chen C, Krausz KW, Shah YM, et al. (2009). Serum metabolomics reveals irreversible inhibition of fatty acid be ta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 22: 699-707.
16. Chen W, Shockcor JP, Tonge R, et al. (1999). Protein and nonprotein cysteinyl thiol modification by N-acetyl-p-benzoquinone imine via a novel ipso adduct. Biochemistry 38:8159-8166.
17. Clayton TA, Baker D, Lindon JC, et al. (2009). Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 106: 14728-14733.
18. Clayton TA, Lindon JC, Cloarec O, et al. (2006). Pharmacometabonomic phenotyping and personalized drug treatment. Nature 440:1073-1077.
19. Cloarec O, Dumas ME, Craig A, et al. (2 005). Statistical total correlation spectroscopy: An exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 77: 1282-1289.
20. Coen M. (2010). A metabonomic approach for mechanistic exploration of pre-clinical toxicology. Toxicology 278:326-340.
21. Coen M, Hong YS, Cloarec O, et al. (2007). Heteronuclear 1H-31P statistical total correlation NMR spectroscopy of intact liver f or metabolic biomarker assignment: Application to galactosamineinduced hepatotoxicity. Anal Chem 79:8956-8966.
22. Coen M, Lenz EM, Nicholson JK, et al. (2003). An integrated metabonomic investigation of ac etaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol 16:295-303.
23. Coen M, Ruepp SU, Lindon JC, et al. (2004). Integrated application of transcriptomics and metabonomics yields new i nsight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 35: 93-105.
24. Dahl N, Pigg M, Ristoff E, et al. (1997). Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet 6:1147-1152.
25. Dahlin DC, Miwa GT, Lu AY, Nelson SD. (1984). N-acetyl-pbenzoquinone imine: A cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 81:1327-1331.
26. Dai W, Huang Q, Yin P, et al. (2012). Comprehensive and highly sensitive urinary steroid hormone profiling method based on stable isotope-labeling liquid chromatography-mass spectrometry. Anal Chem 84:10245-10251.
27. Dempsey GA, Lyall HJ, Corke CF, Scheinkestel CD. (2000). Pyroglutamic acidemia: A cause of high anion gap metabolic acidosis. Crit Care Med 28:1803-1807.
28. Dona AC, Jimenez B, Sch äfer H, et al. (2014). Precision high throughput proton NMR spectroscopy of human urine, serum and plasma for large-scale metabolic phenotyping. Anal Chem 86: 9887-9894.
29. Dunn WB, Broadhurst D, Begley P, et al. (2011). Procedures for largescale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 6:1060-1083.
30. Ebbels TM, Keun HC, Be ckonert OP, et al. (2007). Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: The consortium on metabonomic toxicology screening approach. J Proteome Res 6:4407-4422.
31. Everett JR, Loo RL, Pullen FS. (2013). Pharmacometabonomics and personalized medicine. Ann Clin Biochem 50:523-545.
32. Geenen S, Du Preez FB, Reed M, et al. (2012). A mathematical modelling approach to assessing the reliability of biomarkers of glutathione metabolism. Eur J Pharm Sci 46:233-243.
33. Geenen S, Guall ar-Hoyas C, Michopoulos F, et al. (2011a). HPLC-MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium. J Pharm Biomed Anal 56:655-663.
34. Ge enen S Michopoulos F Kenna JG et al. (2011b) HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium. J Pharm Biomed Anal 54 1128-1135.
35. Ghauri FY, Mclean AE, Beales D, et al. (1993). Induction of 5-oxoprolinuria in the rat following chronic feeding with N-acetyl 4-aminophenol (paracetamol). Biochem Pharmacol 46: 953-957.
36. Godejohann M, Tseng LH, Braumann U, et al. (2004). Characterization of a paracetamol metabolite using on-line LC-SPE-NMR-MS and a cryogenic NMR probe. J Chromatogr A 1058:191-196.
37. Holmes E, Kinross J, Gibson G R, et al. (2012). Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 4:137.
38. Holmes E, Loo RL, Cloarec O, et al. (2007). Detection of urinary drug metabolite (xenom etabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal Chem 79:2629-2640.
39. Jaeschke H, Williams CD, McGill MR. (2012). Caveats of using acetaminophen hepatotoxicity models for natural product testing. Toxicol Lett 215:40-41.
40. Jaeschke H, Williams CD, McGill MR, Farhood A. (2010). Herbal extracts as hepatoprotectants against acetaminophen hepatotoxicity. World J Gastroenterol 16:2448-2450.
41. Jaeschke H, Williams CD, McGill MR, et al. (2013). Models of druginduced liver injury for evaluation of phytotherapeutics and other natural products. Food Chem Toxicol 55:279-289.
42. Jimenez B, Mirnezami R, Kinross J, et al. (2013). 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic ' 'field-effects'' enables colorectal cancer staging and prognostication. J Proteome Res 12:959-968.
43. Johnson CH, Athersuch TJ, Wilson ID, et al. (2008). Kinetic and J-resolved statistical total correlation NMR spectroscopy approaches to structural information recovery in complex reacting mi xtures: Application to acyl glucuronide intramolecular transacylation reactions. Anal Chem 80:4886-4895.
44. Jollow DJ, Mitchell JR, Potter WZ, et al. (1973). Acetaminopheninduced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 187:195-202.
45. Keun HC, Athersuch TJ, Beckonert O, et al. (2008). Heteronuclear 19F-1H statistical total correlation spectroscopy as a tool in drug metabolism: Study of flucloxacillin biotransformation. Anal Chem 80: 1073-10 79.
46. Keun HC, Ebbels TM, Antti H, et al. (2002). Analytical reproducibility in 1H NMR-based metabonomic urinalysis. Chem Res Toxicol 15: 1380-1386.
47. Lau SS, Monks TJ, Gillette JR. (1984). Multiple reactive metabolites derived from bromobenzene. Drug Metab Dispos 12: 291-296.
48. Lee WM. (2012). Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol 26:3-16.
49. Li F, Lu J, Ma X. (2011). Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol 24: 744-751.
50. Li H, Jia W. (2013). Cometabolism of microbes and host: Implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther 94:574-581.
51. Lindon JC, Keun HC, Ebbels TM, et al. (2005). The Consortium for Metabonomic Toxicology (COMET): Aims, activities and achievements. Pharmacogenomics 6:691-699.
52. Lindon JC, Nicholson JK, Holmes E, et al. (2003). Contemporary issues in toxicology the role of metabonomics in toxicology and its evalu ation by the COMET project. Toxicol Appl Pharmacol 187: 137-146.
53. Madsen R, Lundstedt T, Trygg J. (2010). Chemometrics in metabolomics-A review in human disease diagnosis. Anal Chim Acta 659: 23-33.
54. McGill MR, Sharpe MR, Williams CD, et al. (2012a). The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest 1 22:1574-1583.
55. McGill MR Williams CD Xie Y et al. (2012b) Acetaminopheninduced liver injury in rats and mice: Comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxi city. Toxicol Appl Pharmacol 264 387-394.
56. McGill MR, Li F, Sharpe MR, et al. (2014a). Circulating acylcarnitines as biomarkers of mitochondrial dysfunction after acetaminophen overdose in mice and humans. Arch Toxicol 88: 391-401.
57. McGill MR, Staggs VS, Sharpe MR, et al. (2014b). Serum mitochondrial biomarkers and damage-associated molecular patterns are higher in acetaminophen overdose patients with poor outc ome. Hepatology 60: 1336-1345.
58. Mirnezami R, Jimenez B, Li JV, et al. (2014). Rapid diagnosis and staging of colorectal cancer via high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy of intact tissue biopsies. Ann Surg 259:1138-1149.
59. Nelson SD. (1982). Metabolic activation and drug toxicity. J Med Chem 25:753-765.
60. Nicholls AW, Caddick S, Wilson ID, et al. (1995). High resolution NMR spectroscopic studies on the metabolism and futile deacetylation of 4-hydroxyacetanilide (paracetamol) in the rat. Biochem Pharmacol 49: 11 55-1164.
61. Nicholls AW, Farrant RD, Shockcor JP, et al. (1997). NMR and HPLCNMR spectroscopic studies of futile deacetylation in paracetamol metabolites in rat and man. J Pharm Biomed Anal 15:901-910.
62. Nicholson JK, Connelly J, Lindon JC, Holmes E. (2002). Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1:153-161.
63. Nicholson JK, Holmes E, Kinross J, et al. (2012). Host-gut microbiota metabolic interactions. Science 336:1262-1267.
64. Nicholson JK, Lindon JC, Holmes E. (1999). ' Metabonomics' : Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29:1181-1189.
65. O'Brien LM, Hooper M, Fle mmer M, Marik PE. (2012). Chronic acetaminophen ingestion resulting in severe anion gap metabolic acidosis secondary to 5-oxoproline accumulation: An under diagnosed phenomenon. BMJ Case Rep 2012:pii: Bcrbcr0320126020.
66. Ramautar R, Nevedomskaya E, Mayboroda OA, et al. (2011). Metabolic profiling of human urine by CE-MS using a positively charged capillary coating and comparison with UPLC-MS. Mol Biosyst 7: 194-199.
67. Ramautar R, Som sen GW, De Jong GJ. (2014). CE-MS for metabolomics: Developments and applications in the period 2012-2014. Electrophoresis. doi: 10.1002/elps.201400388. [Epub ahead of print].
68. Robinette SL, Lindon JC, Nicholson JK . (2013). Statistical spectroscopic tools for biomarker discovery and systems medicine. Anal Chem 85: 5297-5303.
69. Saito C, Zwingmann C, Jaeschke H. (2010). Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 51:246-254.
70. Sands CJ, Coen M, Ebbels TM, et al. (2011). Data-driven approach for metabolite relationship recovery in biological 1H NMR data se ts using iterative statistical total correlation spectroscopy. Anal Chem 83: 2075-2082.
71. Shi ZZ, Habib GM, Rhead WJ, et al. (1996). Mutations in the glutathione synthetase gene cause 5-oxoprolinuria. Nat Genet 14:361-365.
72. Shipkova P, Vassallo JD, Aranibar N, et al. (2011). Urinary metabolites of 2-bromoethanamine identified by stable isotope labelling: Evidence for carbamoylation and glutathione conjugatio n. Xenobiotica 41: 144-154.
73. Shockcor JP, Unger SE, Wilson ID, et al. (1996). Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine. Anal Chem 68:4431-4435.
74. Soga T, Baran R, Suematsu M, et al. (2006). Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J B iol Chem 281:16768-16776.
75. Spraul M, Freund AS, Nast RE, et al. (2003). Advancing NMR sensitivity for LC-NMR-MS using a cryoflow probe: Application to the analysis of acetaminophen metabolites in urine. Anal Chem 75: 1536-1541.
76. Spraul M, Hofmann M, Lindon JC, et al. (1994). Evaluation of liquid chromatography coupled with high-field 1H NMR spectroscopy for drug metabolite detection and characterization: The identification of paracetamol metabolites in urine and bile. NMR Biomed 7:295-303.
77. Sun J Schnackenberg LK Beger RD. 2009. Studies of acetaminophen and metabolites in urine and their correlations with toxicity using metabolomics. Drug Metab Lett 3 130-136.
78. Sun J, Schnackenberg LK, Holland RD, et al. (2008). Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS. J Chromatogr B Analyt Technol Biomed Life Sci 871:328-340.
79. Trygg J, Holmes E, Lundstedt T. (2007). Chemometrics in metabonomics. J Proteome Res 6:469-479.
80. Want EJ, Coen M, Masson P, et al. (2010a). Ultra performance liquid chromatography-mass spectrometry profiling of bile acid metabolites in biofluids: Application to experimental toxicology studies. Anal Chem 82:5282-5289.
81. Want EJ, Masson P, Michopoulos F, et al. (2013). Global metabolic profiling of animal and human tissues via UPLC-MS. Nat Protoc 8: 17-32.
82. Want EJ, Wilson ID, Gika H, et al. (2010b). Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 5:1005-1018.
83. Waters NJ, Waterfield CJ, Farrant RD, et al. (2006). Integrated metabonomic analysis of bromobenzene-induc ed hepatotoxicity: Novel induction of 5-oxoprolinosis. J Proteome Res 5:1448-1459.
84. Wilson ID, Nicholson JK. (1988). Solid phase extraction chromatography and NMR spectroscopy (SPEC-NMR) for the rapid identifica tion of drug metabolites in urine. J Pharm Biomed Anal 6:151-165.
85. Winnike JH, Li Z, Wright FA, et al. (2010). Use of pharmacometabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 88:45-51.
86. Woolbright BL, McGill MR, Staggs VS, et al. (2014). Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients. Toxicol Sci 142:436-444.
87. Yamazaki M, Miyake M, Sato H, et al. (2013). Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol 268:79-89.